Angiotensin-Receptor Blockers, Type 2 Diabetes, and Renoprotection

To the Editor: I am surprised that the target systolic blood pressures in three studies of the renoprotective effects of angiotensin-receptor blockers in patients with type 2 diabetes (Sept. 20 issue) 1 – 3 exceeded the threshold of less than 130 mm Hg recommended in the sixth report of the Joint Na...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 346; no. 9; pp. 705 - 707
Main Author Blankfield, Robert P
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 28.02.2002
Subjects
Angiotensin Receptor Antagonists
Antihypertensive Agents - therapeutic use
Blood Pressure
Diabetes Mellitus, Type 2 - complications
Diabetic Nephropathies - drug therapy
Humans
Hypertension - classification
Hypertension - complications
Hypertension - drug therapy
Online AccessGet full text

Cover

More Information
Summary:To the Editor: I am surprised that the target systolic blood pressures in three studies of the renoprotective effects of angiotensin-receptor blockers in patients with type 2 diabetes (Sept. 20 issue) 1 – 3 exceeded the threshold of less than 130 mm Hg recommended in the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI). 4 After treatment, the mean systolic blood pressure for all treatment groups in each study was 140 mm Hg or higher. What kind of example is this for practicing physicians who treat hypertensive patients with diabetes? If one strictly . . .
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJM200202283460912